As reviewed by Ascierto et al. (91), in a Phase I/II trial conducted by Bristol–Myers Squibb (BMS) using α4-1BB monoclonal antibodies for advanced or metastatic solid tumors (NCT00309023), cases of low grade fatigue were witnessed as well as grade 2+ neutropenia, leukopenia, thrombocytopenia, and increases in AST and ALT. The gene discussed is GPT; the disease is neutropenia.